Reverse H&S projects to 17.50

Model: 48 by 08/01/25
https://invst.ly/17wd74
This is a model, not a prediction.

Steady, pardon the late reply.
The short answer is lower premium and higher leverage.
I do not plan to hold to expiration so just a trading vehicle.

Adding Jan 26 20 call at 1.45

Want to hold this line around eight
https://invst.ly/17u2wk

Investor was correct again. AVXL an eight dollar stock. Don't shoot the messenger 😂

Doc, respectfully, any thoughts on this one?
https://www.tizianalifesciences.com/tiziana-life-sciences-expands-phase-2-clinical-trial-for-non-active-secondary-progressive-multiple-sclerosis-to-additional-prestigious-u-s-medical-centers/

Adding Jan 25 20 call at .15
Lottery ticket model: https://invst.ly/17sulh

Respectfully, please make the company aware of your concerns.

I will cease casting pearls before you Imposter.

Au contraire mon frere
https://www.investing.com/academy/

Model: 23 by Christmas
AVXL https://invst.ly/17ozd5
This is a model not a prediction.

Genius Group
Imposter CEO, Husky COO, Frolls Gold CTO 😂

Adding 1K @ 9.11
Steady as she goes

Adding 01/16/26 20 Call @ $2.00

Question for Imposter2014
Will AVXL ever be an $8 stock again?

14 just around the corner
https://invst.ly/17iudp

Journal of Alzheimer's Disease
https://www.j-alz.com/

RGTI spaghetti not ready QBTS bits of shits
IONQ ionic is iconic but the future is photonic
QUBT Nvidia of Quantum

QBTS bits
RGTI spaghetti
IONQ iconic
QUBT photonic

Nvidia of Quantum. The future is photonic.
https://quantumcomputinginc.com/news/press-releases/quantum-computing-inc.-announces-second-purchase-order-for-tfln-photonic-chip-foundry-from-university-of-texas-at-austin

Nvidia of quantum

QBTS Bits chokin'
RGTI Spaghetti croakin'
IONQ Iconic broken
QUBT Cube smokin'
The future is photonic
QuantumNvidia

Cube (QUBT) Nvidia of quantum
Ioniq (IONQ) is iconic but the future is photonic
Bits (QBTS) on the fritz, Spaghetti (RGTI) not ready

Go peck yourself

About Brilaroxazine
Positive topline data from the global Phase 3 RECOVER trial in schizophrenia demonstrated the trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains including reduction in key proinflammatory cytokines implicated in the pathophysiology of schizophrenia and comorbid inflammatory conditions at week 4 with 50 mg of brilaroxazine vs. placebo, with a generally well-tolerated side effect profile comparable to placebo and discontinuation rates lower than placebo. Positive data from a clinical drug-drug interaction (DDI) study investigating the potential effect of the CYP3A4 enzyme on brilaroxazine in healthy subjects supports no clinically significant interaction when combined with a CYP3A4 inhibitors. Reviva believes that a full battery of regulatory compliant toxicology and safety pharmacology studies has been completed for brilaroxazine. Reviva intends to develop brilaroxazine for other neuropsychiatric indications including bipolar disorder, major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD). https://revivapharma.com/reviva-announces-enrollment-update-for-open-label-extension-study-evaluating-brilaroxazine-in-schizophrenia-2/

Brilaroxazine in Schizophrenia, RVPH 1.365 +35.00%
RECOVER Trial OLE Enrollment Status Update as of November 12, 2024
108 patients have completed 1-year (12-month) of treatment, over 250 patients have completed 6-month treatment
Blood and digital biomarkers designed to independently support efficacy
Long-term safety data is a requirement for brilaroxazine’s NDA submission to the FDA, 12 months long-term safety study to complete in Q1 2025
https://revivapharma.com/reviva-announces-enrollment-update-for-open-label-extension-study-evaluating-brilaroxazine-in-schizophrenia-2/